Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
Zentalis Pharmaceuticals, Inc. - common stock (ZNTL)
Company Research
Source: GlobeNewswire
DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback $280.7 million cash, cash equivalents and marketable securities supports runway into late 2027 SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, announced financial results for the third quarter 2025 and highlighted recent operational progress. "We are pleased with our continued disciplined execution of the DENALI clinical trial this quarter, supporting late-stage development of azenosertib as a potential treatment for Cyclin E1-positive platinum-resistant ovarian cancer, and positioning us for an anticipated topline data readout by year end 2026. Our engagement
Show less
Read more
Impact Snapshot
Event Time:
ZNTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZNTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZNTL alerts
High impacting Zentalis Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ZNTL
News
- Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval [Seeking Alpha]Seeking Alpha
- Zentalis Pharmaceuticals (NASDAQ:ZNTL) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ZNTL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall MarketBeat
- Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target lowered by analysts at Morgan Stanley from $8.00 to $4.00. They now have an "equal weight" rating on the stock.MarketBeat
- Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.MarketBeat
- Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its "market perform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
ZNTL
Earnings
- 11/10/25 - Beat
ZNTL
Sec Filings
- 11/12/25 - Form SCHEDULE
- 11/10/25 - Form 10-Q
- 11/10/25 - Form 8-K
- ZNTL's page on the SEC website